NEUP
Neuphoria Therapeutics Inc
NASDAQ: NEUP · HEALTHCARE · BIOTECHNOLOGY
$5.27
+1.54% today
Updated 2026-04-30
Market cap
$27.76M
P/E ratio
—
P/S ratio
1.85x
EPS (TTM)
$-0.69
Dividend yield
—
52W range
$4 – $21
Volume
0.1M
WallStSmart proprietary scores
33
out of 100
Grade: F
Strong Sell
Investment rating
6.0
Growth
B7.0
Quality
B+2.0
Profitability
F6.7
Valuation
B6/9
Piotroski F-Score
Moderate
-7.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$13.50
+156.17%
12-Month target
—
—
Intrinsic (DCF)
$11.93
Margin of safety
+66.39%
Price chart
X-Ray snapshot
Strengths
+ 66.39% below intrinsic value
+ Debt/equity 0.01x — low leverage
Risks
- Altman Z -7.09 — distress zone
- Thin margins at -37.80%
- Negative free cash flow $-6.44M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $277892.00 | $0.00 | $0.00 | $23.95M | $14.99M |
| Net income | $-22.94M | $-21.65M | $-23.19M | $-565773.00 | $1.86M |
| EPS | — | — | — | — | $-0.69 |
| Free cash flow | $-14.97M | $-9.85M | $-14.68M | $77.23M | $-6.44M |
| Profit margin | -8,253.64% | — | — | -2.36% | -37.80% |
Peer comparison
Smart narrative
Neuphoria Therapeutics Inc trades at $5.27. Our Smart Value Score of 33/100 indicates the stock is weak. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of -7.09, it sits in the distress. TTM revenue stands at $14.99M. with profit margins at -37.80%. Our DCF model estimates intrinsic value at $11.93.
Frequently asked questions
What is Neuphoria Therapeutics Inc's stock price?
Neuphoria Therapeutics Inc (NEUP) trades at $5.27.
Is Neuphoria Therapeutics Inc overvalued?
Smart Value Score 33/100 (Grade F, Strong Sell). DCF value $11.93.
What is the price target of Neuphoria Therapeutics Inc (NEUP)?
The analyst target price is $13.50, representing +156.2% upside from the current price of $5.27.
What is the intrinsic value of Neuphoria Therapeutics Inc (NEUP)?
Based on our DCF model, intrinsic value is $11.93, a +66.4% margin of safety versus $5.27.
What is Neuphoria Therapeutics Inc's revenue?
TTM revenue is $14.99M.
Piotroski F-Score?
6/9 — moderate financial health.
Altman Z-Score?
-7.09 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.85x
ROE-26.10%
Beta—
50D MA$4.51
200D MA$6.71
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—